Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Observational Study of Canadian Patients (6 Years or Older) Receiving Dupixent® for Moderate to Severe Atopic Dermatitis
- Conditions
- Moderate to Severe Atopic Dermatitis
- First Posted Date
- 2023-10-25
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 305
- Registration Number
- NCT06099704
- Locations
- 🇨🇦
Investigational Site Number : 1240008, Peterborough, Ontario, Canada
🇨🇦Investigational Site Number : 1240019, Calgary, Alberta, Canada
🇨🇦Investigational Site Number : 1240021, Calgary, Alberta, Canada
A Non-interventional Study to Describe the Dupilumab Long-term Treatment, Safety and Patient Reported Outcomes in Chronic Nodular Prurigo (Prurigo Nodularis) in Clinical Routine
- First Posted Date
- 2023-10-18
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 150
- Registration Number
- NCT06087627
- Locations
- 🇩🇪
Investigational site number: 001, Berlin, Germany
🇩🇪Investigational Site Number: 007, Hamburg, Germany
🇩🇪Investigational Site Number: 005, Düren, Germany
A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction
- Conditions
- Lung Transplant Rejection
- Interventions
- First Posted Date
- 2023-10-13
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 180
- Registration Number
- NCT06082037
- Locations
- 🇺🇸
University of Alabama at Birmingham- Site Number : 8400026, Birmingham, Alabama, United States
🇺🇸St. Joseph's Hospital and Medical Center- Site Number : 8400019, Phoenix, Arizona, United States
🇺🇸University of California Los Angeles Medical Center- Site Number : 8400020, Los Angeles, California, United States
A Study to Evaluate SAR441566 Efficacy and Safety in Adults With Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 264
- Registration Number
- NCT06073093
- Locations
- 🇿🇦
Investigational Site Number : 7100002, Cape Town, South Africa
🇪🇸Investigational Site Number : 7240003, Málaga, Spain
🇨🇿Investigational Site Number : 2030006, Brno, Czechia
A Study to Evaluate Efficacy and Safety of SAR441566 in Adults With Plaque Psoriasis
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2025-01-23
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 221
- Registration Number
- NCT06073119
- Locations
- 🇺🇸
FXM Clinical Research Miami, LLC- Site Number : 8400016, Miami, Florida, United States
🇺🇸Center for Clinical Studies, LTD. LLP- Site Number : 8400007, Houston, Texas, United States
🇺🇸Center for Clinical Studies, LTD, LLP- Site Number : 8400013, Webster, Texas, United States
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SAR442501 in Pediatric Participants With Achondroplasia
- First Posted Date
- 2023-10-04
- Last Posted Date
- 2025-02-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 16
- Registration Number
- NCT06067425
- Locations
- 🇮🇹
Investigational Site Number : 3800002, Milan, Lombardia, Italy
🇨🇳Investigational Site Number : 1560001, Wuhan, China
🇦🇺Investigational Site Number : 0360001, Parkville, Victoria, Australia
Study of Drug-drug Interaction of the Effects of Gemfibrozil and Rifampicin on SAR442168 in Healthy Adult Subjects
- Conditions
- Multiple Sclerosis
- Interventions
- First Posted Date
- 2023-10-03
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 30
- Registration Number
- NCT06064539
- Locations
- 🇺🇸
Prism Research-Site Number:8400001, Saint Paul, Minnesota, United States
An Observational, Retrospective Multicentre Medical Record Review to Describe the Post-authorisation Early Clinical Experience of Dupilumab in the Treatment of Adult Severe Asthma
- Conditions
- Asthma
- Interventions
- Other: No intervention
- First Posted Date
- 2023-10-03
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 144
- Registration Number
- NCT06064526
- Locations
- 🇫🇷
Sanofi-Aventis, France, Chilly-Mazarin, France
Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: SAR444656 (KT-474)Drug: Placebo
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 200
- Registration Number
- NCT06058156
- Locations
- 🇬🇷
Investigational Site Number : 3000002, Thessaloniki, Greece
🇵🇱Investigational Site Number: 6160004, Gdansk, Pomorskie, Poland
🇺🇸Clear Dermatology & Aesthetics Center Site Number: 8400003, Scottsdale, Arizona, United States
Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2023/24
- Conditions
- Influenza Immunization (Healthy Volunteers)
- Interventions
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 2078
- Registration Number
- NCT06059456
- Locations
- 🇫🇮
Investigational Site Number : 2460001, Helsinki, Finland
🇩🇪Investigational Site Number : 2760010, Martinsried, Germany
🇩🇪Investigational Site Number : 2760003, Martinsried, Germany